AstraZeneca Sheds Assets After its Trial Failure

AstraZeneca (NYSE: AZN) has been on the receiving end of three different purchases in the first five days of October, selling licenses to three of its non-core assets for a combined upfront payment of $450 million. Its selling spree occurred in tandem with the announced trial failure of its blood thinner Brilinta (ticagrelor), which failed […]

MedImmune Parcels Out an Investgational Blood Cancer Candidate

Last week MedImmune Ltd., the biotech arm of AstraZeneca plc (NYSE: AZN), announced two placements for its investigational compound, MEDI4736. The first announcement was with Juno Therapeutics Inc. (NASDAQ: JUNO), which signed an non-exclusive agreement to test its own investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates with MedImmune’s programmed cell death ligand 1 […]

Celgene’s Busy Week

It wasn’t until the final week in April that Celgene Corporation (NASDAQ: CELG) took the title of top deal maker for the month. The single acquisition on the books as of April 24 was its collaboration with MedImmune (NYSE: AZN) on its anti-PD-L1 inhibitor MEDI4736, with $450 million in cash upfront. On April 27, CELG […]